Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Sun Yat-sen University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07353827CT.gov FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma | — | Not Yet Recruiting | — | — | — |
NCT06632093CT.gov HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC | — | Recruiting | — | — | — |
NCT06632106CT.gov HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC | — | Active Not Recruiting | — | — | — |
NCT06631326CT.gov HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416) | — | Completed | — | — | — |
NCT03607643CT.gov A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | — | Unknown | — | — | — |
NCT03668418CT.gov Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | — | Unknown | — | — | — |
NCT02042443CT.gov Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT00471484CT.gov Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery | — | Unknown | — | — | — |
NCT00537121CT.gov Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer | — | Completed | — | — | — |
NCT00507585CT.gov Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin | — | Completed | — | — | — |
Show 1 more trialShow fewer
NCT00019474CT.gov Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Liver Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fluorouracilum (this asset) | Sun Yat-sen University | P3 | B · 63 |
| Dexmedetomidine | Uppsala University Hospital | P4 | BBB |
| Adriamycin | Shanghai Zhongshan Hospital | P4 | BB |
| Oxaliplatin | Sun Yat-sen University | P3 | BB |
| Jnj-54135419 | The Second Affiliated Hospital of Chongqing Medical University | P4 | BB |
| Tranexamic Acid | Konkuk University Medical Center | P4 | BB |
| Hepatitis B Virus Vaccine | Eunice Dube | P4 | BB |
| Sorafenib | First Affiliated Hospital Xi'an Jiaotong University | P3 | BB |
| Gardasil 9 Vaccine | Eunice Dube | P4 | BB |
+42 more in the Liver Cancer cohort
Other indications for Fluorouracilum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 77 |
| Rectal Cancer | — | P3 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fluorouracilum in Liver Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fluorouracilum-liver-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →